Investing.com – GSK(LON:GSK)'s second-quarter results exceeded expectations with strong sales and profits, leading to an upward revision of the outlook. However, a cut in the vaccine sales target has led to a dip in the company’s shares.
Total sales reached £7.9 billion, up 13% year-over-year. ore operating profit surged 18%, reflecting improved operational efficiency, while core EPS grew 13%. Specialty Medicines led the way with a 22% increase, bolstered by new oncology and HIV products.
GSK's overall sales were 5% ahead of consensus in the second quarter. Specialty medicines performed particularly well, exceeding expectations by 6%, driven by strong sales of Dovato and a launch of Ojjaara, said analysts at Jefferies in a note.
General medicines saw a 17% beat, largely due to the success of Trelegy and legacy drugs. However, vaccine sales missed expectations by 9%, primarily due to weak Shingrix sales in the US, despite Arexvy performing as expected, the analysts added.
This strong top-line performance drove adjusted EBIT and EPS to beat expectations by 12%, underscoring the company's robust financial health.
GSK has upgraded its full-year outlook, anticipating sales growth between 7% and 9%, core operating profit growth of 11% to 13%, and core EPS growth of 10% to 12%, all at constant exchange rates.
Jefferies retains a 'Buy' rating on GSK, emphasizing the company's strong growth profile in long-acting HIV injectables and new pipeline launches. Additionally, the potential Zantac class action settlement presents a significant risk-reward opportunity.
Should you invest $2,000 in GSK right now?
With GSK making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed GSK alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including GSK, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is GSK poised for similar growth? Don't miss the opportunity to find out.
Reveal Undervalued Stocks Now